Global Antiglaucoma Drugs Market Trends And Strategies Of Major Players In The Antiglaucoma Drugs Market 2021-2030

28 Oct, 2021

The antiglaucoma drug market consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and other. The market does not include the sale of biologics used for the treatment of glaucoma.

Global Antiglaucoma Drugs Market Size And Drivers:

The global antiglaucoma drugs market is expected to grow from $5.76 billion in 2020 to $6.47 billion in 2021 at a compound annual growth rate (CAGR) of 12.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.17 billion in 2025 at a CAGR of 6%. Incidence of glaucoma increases with age and due to increase in the geriatric population worldwide, governments are launching initiatives to promote awareness on glaucoma and other eye disorders.

Request For A Sample For The Global Antiglaucoma Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3803&type=smp

Trends In The Global Antiglaucoma Drugs Market

Companies in the antiglaucoma drugs market are developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients. Most of the combinations therapies are fixed dose drugs as it offers patient the ease of consumption when compared to non-fixed combinations. Alcon launched a combination drug, Simbrinza which is fixed combination of Brinzolamide and Brimonidine, to help patients in reducing the intake of multiple drugs for glaucoma. Rocklatan is a combination of a rho kinase inhibitor and a prostaglandin analog. Combigan is a combination of beta blocker and alpha agonist. Cosopt is a combination of beta blocker and carbonic anhydrase inhibitor.

Global Antiglaucoma Drugs Market Segments:
The global antiglaucoma drugs market is further segmented –
By Product Type: Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others
By Disease Condition Type: Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma
By Type: Hospital Prescription Drugs, Over-the-counter Drugs
By Geography: The global antiglaucoma drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Antiglaucoma Drugs Market At:

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Antiglaucoma Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides antiglaucoma drugs market overviews, analyzes and forecasts market size and growth for the global antiglaucoma drugs market, antiglaucoma drugs market share, antiglaucoma drugs market players, antiglaucoma drugs market segments and geographies, antiglaucoma drugs market’s leading competitors’ revenues, profiles and market shares. The antiglaucoma drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.